Bonsai 27B is a multi-billion parameter model small enough to fit into a smartphone. It’s useful for dev and research work, ...

Use Spring MVC MultipartFile, Java Path APIs and the browser fetch API to upload files asynchronously and save them safely on the server. Learn how JAR files relate to ZIP archives, how to extract ...

Mahdi is the founder of ScienceCodons and a Medical Biotechnologist with a deep passion for computational biology. Holding an M.Sc. in Medical Biotechnology, he specializes in transforming complex ...

Fatemeh is a Medical Biotechnologist and researcher. With extensive expertise in genetic engineering, molecular cloning, and cancer biology, she combines her rigorous laboratory background with ...

Natural disaster preparation is one of the biggest reasons to own a reliable backup power source, and solar generators offer a more convenient alternative to traditional gas-powered options. Solar ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...

The total number of books published in the U.S. in 2025 with ISBN numbers jumped 32.5% over 2024, to more than four million books, according to statistics compiled by Bowker. The increase was led by ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...